What is Allogene Therapeutics's D&A?

Allogene Therapeutics (ALLO) reported D&A of $2.87M in Q1 2026.

How has Allogene Therapeutics's D&A changed year-over-year?

Allogene Therapeutics's D&A decreased by 7.4% year-over-year, from $3.1M to $2.87M.

What is the long-term trend for Allogene Therapeutics's D&A?

Over 4 years (2021 to 2025), Allogene Therapeutics's D&A has grown at a 4.3% compound annual growth rate (CAGR), from $10.45M to $12.36M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Allogene Therapeutics ALLO D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

PrecigenPGEN

$1.1M+74.7%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

Sana BiotechnologySANA

$2.39M-34.5%

Immix Biopharma, Inc.IMMX

$91.58K+140%

Vor BiopharmaVOR

$28K-96.6%

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's D&A?: Allogene Therapeutics (ALLO) reported D&A of $2.87M in Q1 2026.
How has Allogene Therapeutics's D&A changed year-over-year?: Allogene Therapeutics's D&A decreased by 7.4% year-over-year, from $3.1M to $2.87M.
What is the long-term trend for Allogene Therapeutics's D&A?: Over 4 years (2021 to 2025), Allogene Therapeutics's D&A has grown at a 4.3% compound annual growth rate (CAGR), from $10.45M to $12.36M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.